PH12017500403A1 - Anti-il-25 antibodies and uses thereof - Google Patents

Anti-il-25 antibodies and uses thereof

Info

Publication number
PH12017500403A1
PH12017500403A1 PH12017500403A PH12017500403A PH12017500403A1 PH 12017500403 A1 PH12017500403 A1 PH 12017500403A1 PH 12017500403 A PH12017500403 A PH 12017500403A PH 12017500403 A PH12017500403 A PH 12017500403A PH 12017500403 A1 PH12017500403 A1 PH 12017500403A1
Authority
PH
Philippines
Prior art keywords
antibodies
human
bind
disease
certain embodiments
Prior art date
Application number
PH12017500403A
Other languages
English (en)
Inventor
Jamie M Orengo
Jeanne Allinne
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54207847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017500403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PH12017500403A1 publication Critical patent/PH12017500403A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
PH12017500403A 2014-09-23 2017-03-03 Anti-il-25 antibodies and uses thereof PH12017500403A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054167P 2014-09-23 2014-09-23
PCT/US2015/051407 WO2016049000A2 (en) 2014-09-23 2015-09-22 Anti-il-25 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PH12017500403A1 true PH12017500403A1 (en) 2017-07-17

Family

ID=54207847

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017500403A PH12017500403A1 (en) 2014-09-23 2017-03-03 Anti-il-25 antibodies and uses thereof

Country Status (18)

Country Link
US (3) US9840557B2 (enExample)
EP (1) EP3197914B1 (enExample)
JP (2) JP6694877B2 (enExample)
KR (1) KR102576368B1 (enExample)
CN (1) CN107207589B (enExample)
AU (1) AU2015321517B2 (enExample)
CA (1) CA2961517C (enExample)
CL (2) CL2017000703A1 (enExample)
CO (1) CO2017003072A2 (enExample)
EA (1) EA036658B1 (enExample)
IL (1) IL251001B (enExample)
MA (1) MA40106A1 (enExample)
MX (1) MX2017003841A (enExample)
MY (1) MY185832A (enExample)
PH (1) PH12017500403A1 (enExample)
SG (2) SG11201701712WA (enExample)
WO (1) WO2016049000A2 (enExample)
ZA (1) ZA201701663B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6694877B2 (ja) 2014-09-23 2020-05-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｉｌ−２５抗体およびその使用
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
CN107213463A (zh) * 2017-05-24 2017-09-29 清华大学 白介素25在银屑病的发育中的作用
EP3883965A4 (en) * 2018-11-19 2022-10-12 Suzhou Kanova Biopharmaceutical Co., Ltd. ANTI-IL-25 ANTIBODIES AND THEIR USE
AU2020407124A1 (en) 2019-12-20 2022-07-21 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2022150660A1 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
US20240400671A1 (en) * 2021-10-05 2024-12-05 Richard A. Shimkets Monoconal antibodies to il-25 and uses thereof
KR20240161653A (ko) * 2022-02-24 2024-11-12 시노맙 바이오사이언스 리미티드 알라르민에 대한 이중 특이적 결합 단백질 및 이의 용도
CN119451698A (zh) * 2023-03-31 2025-02-14 新石生物制药有限公司 抗il-25抗体及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
SG184195A1 (en) * 2010-03-30 2012-11-29 Janssen Biotech Inc Humanized il-25 antibodies
WO2012097126A2 (en) * 2011-01-13 2012-07-19 The University Of Maryland, Baltimore Il-25 treatment of obesity and metabolic disorders
DK2858670T3 (en) * 2012-06-12 2018-10-22 Orega Biotech Antagonists of IL-17 isoforms and their applications
JP6694877B2 (ja) 2014-09-23 2020-05-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｉｌ−２５抗体およびその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
WO2019043064A1 (de) 2017-08-30 2019-03-07 Blaess Markus Zusammensetzung zur topischen behandlung von nicht-mikroorganismus-verursachten entzündlichen haut- und schleimhauterkrankungen

Also Published As

Publication number Publication date
NZ730105A (en) 2024-01-26
CA2961517C (en) 2023-05-02
MY185832A (en) 2021-06-11
US20200262912A1 (en) 2020-08-20
CN107207589B (zh) 2021-04-06
ZA201701663B (en) 2023-04-26
MA40106A1 (fr) 2018-06-29
CA2961517A1 (en) 2016-03-31
EA201790441A1 (ru) 2017-08-31
EP3197914A2 (en) 2017-08-02
US20180057583A1 (en) 2018-03-01
SG10201913084PA (en) 2020-03-30
MX2017003841A (es) 2018-02-23
JP2017533888A (ja) 2017-11-16
WO2016049000A2 (en) 2016-03-31
KR20170063671A (ko) 2017-06-08
BR112017005692A2 (pt) 2017-12-12
US20160083466A1 (en) 2016-03-24
US10640558B2 (en) 2020-05-05
CO2017003072A2 (es) 2017-06-30
IL251001A0 (en) 2017-04-30
EA036658B1 (ru) 2020-12-04
US11542326B2 (en) 2023-01-03
JP2020075926A (ja) 2020-05-21
CL2018003608A1 (es) 2019-03-15
KR102576368B1 (ko) 2023-09-08
JP6916319B2 (ja) 2021-08-11
IL251001B (en) 2021-04-29
EP3197914B1 (en) 2024-02-07
JP6694877B2 (ja) 2020-05-20
SG11201701712WA (en) 2017-04-27
AU2015321517A1 (en) 2017-04-06
CL2017000703A1 (es) 2017-12-29
WO2016049000A3 (en) 2016-05-06
US9840557B2 (en) 2017-12-12
CN107207589A (zh) 2017-09-26
AU2015321517B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
PH12017500403A1 (en) Anti-il-25 antibodies and uses thereof
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
MX2023004306A (es) Un antagonista de il-4r para usarse en prevenir o tratar la alergia.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
PH12016500182A1 (en) Anti-activin a antibodies and uses thereof
MX381456B (es) Regulador de ph de transduccion.
PH12016501547A1 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
NZ710726A (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
CA2939931C (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
MX2020006494A (es) Anticuerpos de cadena pesada que se unen a cd22.
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
MX362854B (es) Siarn y su uso en los metodos y composiciones para el tratamiento y/o prevencion de enfermedades de los ojos.
WO2015169811A3 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
MX368972B (es) Composiciones de glicoproteínas sialiladas y usos de estas.
Lauritzen et al. Two properties of endomorphisms of Weyl algebras
MY186726A (en) Anti-activin a antibodies and uses thereof